ADMA Biologics to Virtually Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
02 sept. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN
16 août 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated...
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
11 août 2021 16h05 HE
|
ADMA Biologics, Inc.
Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year ADMA Now Anticipates Exiting 2021...
ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System
10 août 2021 16h30 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and CONYERS, Ga., Aug. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM® and NABI-HB®
09 août 2021 07h00 HE
|
ADMA Biologics, Inc.
ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes BIVIGAM 100 mL Vial and NABI-HB 1 mL Vial Now Commercially Available to U.S. Healthcare Providers RAMSEY,...
ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021
04 août 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection
20 juil. 2021 07h00 HE
|
ADMA Biologics, Inc.
Approval for VanRx Fill-Finish Machine Expected in the Second Half of 2021 All Supply Chain Robustness Initiatives Remain on Schedule RAMSEY, N.J. and BOCA RATON, Fla., July 20, 2021 (GLOBE...
ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference
14 juin 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics to Participate in the Jefferies Virtual Healthcare Conference
26 mai 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress and Accomplishments
12 mai 2021 16h05 HE
|
ADMA Biologics, Inc.
Achieved First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020 Significantly Expanded Total Asset Value to $235.7 Million, Including $94.1 Million in Inventories ...